BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 28267534)

  • 1. Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy.
    Anderson TL; Glazebrook KN; Murphy BL; Viers LD; Hieken TJ
    Eur J Radiol; 2017 Apr; 89():163-168. PubMed ID: 28267534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
    van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment.
    Yoo TK; Chang JM; Shin HC; Han W; Noh DY; Moon HG
    BMC Cancer; 2017 May; 17(1):389. PubMed ID: 28569197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Samiei S; de Mooij CM; Lobbes MBI; Keymeulen KBMI; van Nijnatten TJA; Smidt ML
    Ann Surg; 2021 Apr; 273(4):694-700. PubMed ID: 33201095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
    van Loevezijn AA; van der Noordaa MEM; Stokkel MPM; van Werkhoven ED; Groen EJ; Loo CE; Elkhuizen PHM; Sonke GS; Russell NS; van Duijnhoven FH; Vrancken Peeters MTFD
    Breast Cancer Res Treat; 2022 May; 193(1):37-48. PubMed ID: 35239072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid
    de Mooij CM; Samiei S; Mitea C; Lobbes MBI; Kooreman LFS; Heuts EM; Beets-Tan RGH; van Nijnatten TJA; Smidt ML
    Clin Radiol; 2022 Oct; 77(10):e732-e740. PubMed ID: 35850866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?
    Barrio AV; Mamtani A; Eaton A; Brennan S; Stempel M; Morrow M
    Ann Surg Oncol; 2017 Mar; 24(3):645-651. PubMed ID: 28130619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.
    Reis J; Boavida J; Tran HT; Lyngra M; Reitsma LC; Schandiz H; Melles WA; Gjesdal KI; Geisler J; Geitung JT
    BMC Cancer; 2022 Jun; 22(1):702. PubMed ID: 35752785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
    Donker M; Straver ME; Wesseling J; Loo CE; Schot M; Drukker CA; van Tinteren H; Sonke GS; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg; 2015 Feb; 261(2):378-82. PubMed ID: 24743607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.
    Nakamura R; Yamamoto N; Miyaki T; Itami M; Shina N; Ohtsuka M
    Breast Cancer; 2018 Jan; 25(1):86-93. PubMed ID: 28735457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extra-axillary nodal metastases in breast cancer: comparison of ultrasound, MRI, PET/CT, and CT.
    Chung HL; Shin K; Sun J; Leung JWT
    Clin Imaging; 2021 Nov; 79():113-118. PubMed ID: 33933824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.